Alphabet and EmblemHealth returned to help supply $53.5m for the community-focused care provider, bringing its overall funding to nearly $140m.

Adimab's coronavirus antibody spinoff has launched with series A financing from investors including GV as it prepares for its first clinical trials.

The WndrCo-backed recruitment platform developer has taken its total funding to $48m with a round announced alongside a new diversity tool.

Intel Capital returned for a series A round that helped the data analytics platform developer boost its overall funding to $20m.

VC firm Artis Ventures led a round for robotic surgery software developer Activ 10 months after its Sony-backed series A funding.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The oncology therapy developer has gone public in an upsized offering that provided an exit to Third Rock Ventures.

Merck & Co backed a $14m series B for SAB Biotherapeutics, which is developing drugs for two forms of coronavirus including Covid-19.

The oncology therapy developer has gone public in an upsized offering that provided exits for SoftBank Vision Fund and Alphabet's GV unit.

The round valued the Western Digital-backed file management technology provider in excess of $1.2bn and pushed its total funding past $350m.